Download PDF
Semin Thromb Hemost 2012; 38(01): 79-94
DOI: 10.1055/s-0031-1300954
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges

Antonio Coppola
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy
,
Annarita Tagliaferri
2   Regional Reference Centre for Inherited Bleeding Disorders, University Hospital, Parma, Italy
,
Mirko Di Capua
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy
,
Massimo Franchini
3   Immunohematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
07 February 2012 (online)

    Permissions and Reprints

Abstract

Recurrent joint bleeding leading to progressive musculoskeletal damage (hemophilic arthropathy), in spite of on-demand replacement with deficient factor concentrates, is the clinical hallmark of severe hemophilia A and B (i.e., the congenital deficiencies of coagulation factors VIII and IX with circulating levels <1 IU/dL). Fifty years of clinical experience, which began in Northern Europe and then initiated in other European countries and in North America, up to the recent randomized clinical trials, have provided definitive evidence that preventing bleeding from an early age through long-term regular prophylactic concentrate infusions limits the adverse clinical consequences of arthropathy and its complications in the quality of life of hemophilic children. Primary prophylaxis started after the first joint bleed and/or before the age of 2 is now the evidence-based, first-choice treatment in severe hemophilia. Interestingly, recent data also suggest a role for early prophylaxis in preventing inhibitor development, the most serious complication of hemophilia therapy. Secondary prophylaxis is aimed to avoid (or delay) the progression of arthropathy. The earlier the treatment is started, the better the outcomes in joint status and quality of life. Although prophylaxis has radically transformed the natural history of severe hemophilia, relevant barriers to its implementation and diffusion remain. Beyond the obvious economic constraints and problems with venous access and long-term adherence, uncertainties regarding the optimal prophylaxis regimen require further evaluation in prospective studies to optimize approaches based on definite outcome measures and cost-effectiveness/cost-utility analyses. Scientific evidence, current clinical strategies, and open issues of prophylaxis in children with hemophilia will be addressed in this review.

Keywords

bleeding - children - hemophilia - hemophilic arthropathy - prophylaxis - quality of life
 

  • References

  • 1 Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-242
    PubMedGoogle Scholar
  • 3 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; ;( (Suppl 77) 77-, 3–132
    PubMedGoogle Scholar
  • 4 van den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007; 5 (Suppl 1) 151-156
    CrossrefPubMedGoogle Scholar
  • 5 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12 (Suppl 3) 117-121
    CrossrefPubMedGoogle Scholar
  • 7 Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl 3) 10-18
    PubMedGoogle Scholar
  • 8 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1) 25-32
    CrossrefPubMedGoogle Scholar
  • 9 Berntorp E, Boulyjenkov V, Brettler D , et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73 (5) 691-701
    PubMedGoogle Scholar
  • 10 Srivastava A, Giangrande P, Poon MC , et al. Guidelines for the Management of Hemophilia. World Federation of Hemophilia, 2005. Available at: http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf . Last accessed 16 September 2011
    PubMedGoogle Scholar
  • 11 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
    CrossrefPubMedGoogle Scholar
  • 12 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9 (4) 700-710
    CrossrefPubMedGoogle Scholar
  • 13 Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia 2004; 10 (Suppl 4) 9-13
    PubMedGoogle Scholar
  • 14 Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy — global progress towards optimal care. Haemophilia 2006; 12 (1) 75-81
    PubMedGoogle Scholar
  • 15 Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101 (4) 674-681
    PubMedGoogle Scholar
  • 16 Aledort LM, Haschmeyer RH, Pettersson H ; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (4) 391-399
    CrossrefPubMedGoogle Scholar
  • 17 Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3) (Suppl 2) 3-6
    PubMedGoogle Scholar
  • 18 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149 (149) 153-159
    PubMedGoogle Scholar
  • 19 Fischer K, van der Bom JG, Mauser-Bunschoten EP , et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99 (7) 2337-2341
    CrossrefPubMedGoogle Scholar
  • 20 Gringeri A, von Mackensen S, Auerswald G , et al; Haemo-QoL Study. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10 (Suppl 1) 26-33
    CrossrefPubMedGoogle Scholar
  • 21 Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?—The German experience. Haemophilia 1998; 4 (4) 413-417
    CrossrefPubMedGoogle Scholar
  • 22 van den Berg HM, Fischer K, Mauser-Bunschoten EP , et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112 (3) 561-565
    CrossrefPubMedGoogle Scholar
  • 23 Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9 (3) 272-278
    CrossrefPubMedGoogle Scholar
  • 24 Yee TT, Beeton K, Griffioen A , et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8 (2) 76-82
    CrossrefPubMedGoogle Scholar
  • 25 Berntorp E, Astermark J, Björkman S , et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl 1) 1-4
    PubMedGoogle Scholar
  • 26 Donadel-Claeyssens S ; European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12 (2) 124-127
    CrossrefPubMedGoogle Scholar
  • 27 Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?. Haemophilia 2004; 10 (2) 147-157
    PubMedGoogle Scholar
  • 28 Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23 (6) 267-274
    CrossrefPubMedGoogle Scholar
  • 29 National Hemophilia Foundation. Medical and Scientific Advisory Council. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 170. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=582 . Accessed on September 16, 2011
    PubMedGoogle Scholar
  • 30 Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105 (4) 1109-1113
    CrossrefPubMedGoogle Scholar
  • 31 Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?. Haemophilia 2001; 7 (1) 99-102
    CrossrefPubMedGoogle Scholar
  • 32 Richards M, Williams M, Chalmers E , et al; Paediatric Working Party of the United Kingdom Haemophilia Doctors’ Organisation. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149 (4) 498-507
    CrossrefPubMedGoogle Scholar
  • 33 Feldman BM, Pai M, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (6) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 34 Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM ; Canadian Hemophilia Primary Prophylaxis Study Group. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9 (5) 1067-1069
    CrossrefPubMedGoogle Scholar
  • 35 Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 2010; 16 (Suppl 2) 4-9
    PubMedGoogle Scholar
  • 36 Meunier S, Trossaërt N, Berger C , et al. French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemopiliac arthropathy. Arch Pediatr 2009; 16: 1571-1578
    CrossrefPubMedGoogle Scholar
  • 37 Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13 (Suppl 2) 16-22
    CrossrefPubMedGoogle Scholar
  • 38 Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22 (5) 251-258
    PubMedGoogle Scholar
  • 39 Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47 (2) 113-117
    CrossrefPubMedGoogle Scholar
  • 40 Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92 (4) 973-978
    CrossrefPubMedGoogle Scholar
  • 41 Cohen A, White E, Bernstein C , et al. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion 1997; 37: 534-535
    PubMedGoogle Scholar
  • 42 Tagliaferri A, Franchini M, Coppola A , et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14 (5) 945-951
    CrossrefPubMedGoogle Scholar
  • 43 Franchini M, Coppola A, Molinari AC , et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 2009; 15 (2) 578-586
    CrossrefPubMedGoogle Scholar
  • 44 Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005; 2 (2) CD003429
    PubMedGoogle Scholar
  • 45 Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; 9: CD003429
    PubMedGoogle Scholar
  • 46 Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl 1) 57-63, discussion 63–64
    PubMedGoogle Scholar
  • 47 Doria AS, Lundin B, Kilcoyne RF , et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia 2005; 11 (3) 245-253
    CrossrefPubMedGoogle Scholar
  • 48 von Mackensen S, Bullinger M ; Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10 (Suppl 1) 17-25
    PubMedGoogle Scholar
  • 49 Colvin BT, Astermark J, Fischer K , et al; Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14 (2) 361-374
    CrossrefPubMedGoogle Scholar
  • 50 Vidler V. Teaching parents advanced clinical skills. Haemophilia 1999; 5 (5) 349-353
    CrossrefPubMedGoogle Scholar
  • 51 De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14 (5) 931-938
    CrossrefPubMedGoogle Scholar
  • 52 Collins PW, Blanchette VS, Fischer K , et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (3) 413-420
    CrossrefPubMedGoogle Scholar
  • 53 Fischer K, Collins P, Björkman S , et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia 2011; 17 (3) 433-438
    CrossrefPubMedGoogle Scholar
  • 54 Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6 (6) 649-657
    CrossrefPubMedGoogle Scholar
  • 55 Hill FG, Ljung R ; European Paediatric Network for Haemophilia Management. Third and fourth Workshops of the European Paediatric Network for Haemophilia Management. Haemophilia 2003; 9 (2) 223-228
    CrossrefPubMedGoogle Scholar
  • 56 Hilliard P, Funk S, Zourikian N , et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12 (5) 518-525
    CrossrefPubMedGoogle Scholar
  • 57 Lundin B, Babyn P, Doria AS , et al; International Prophylaxis Study Group. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11 (2) 109-115
    CrossrefPubMedGoogle Scholar
  • 58 Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010; 16 (Suppl 5) 107-114
    PubMedGoogle Scholar
  • 59 Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia 2009; 15 (5) 1168-1171
    CrossrefPubMedGoogle Scholar
  • 60 Melchiorre D, Linari S, Innocenti M , et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia 2011; 17 (1) 112-117
    CrossrefPubMedGoogle Scholar
  • 61 Blanchette VS, Shapiro AD, Liesner RJ , et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6 (8) 1319-1326
    CrossrefPubMedGoogle Scholar
  • 62 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10) 989-998
    CrossrefPubMedGoogle Scholar
  • 63 Collins PW, Björkman S, Fischer K , et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8 (2) 269-275
    CrossrefPubMedGoogle Scholar
  • 64 Carlsson M, Berntorp E, Bjorkman S , et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of hemophilia A. Haemophilia 1997; 3: 96-101
    CrossrefPubMedGoogle Scholar
  • 65 Morfini M, Lee M, Messori A ; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66 (3) 384-386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10 (6) 689-697
    CrossrefPubMedGoogle Scholar
  • 67 Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 (Suppl 1) 94-99, discussion 100
    PubMedGoogle Scholar
  • 68 Shapiro AD, Korth-Bradley J, Poon M-C. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11 (6) 571-582
    CrossrefPubMedGoogle Scholar
  • 69 Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia 2003; 9 (Suppl 1) 75-81, discussion 82
    CrossrefPubMedGoogle Scholar
  • 70 Coppola A, Cerbone AM, Mancuso G, Mansueto MF, Mazzini C, Zanon E. Confronting the psychological burden of haemophilia. Haemophilia 2011; 17 (1) 21-27
    CrossrefPubMedGoogle Scholar
  • 71 van Genderen FR, van Meeteren NL, van der Bom JG , et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10 (5) 565-571
    CrossrefPubMedGoogle Scholar
  • 72 Gringeri A, Von Mackensen S. Quality of life in haemophilia. Haemophilia 2008; 14 (Suppl 3) 19-25
    CrossrefPubMedGoogle Scholar
  • 73 Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?. Pediatr Blood Cancer 2006; 47 (3) 305-311
    CrossrefPubMedGoogle Scholar
  • 74 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (4) 418-435
    CrossrefPubMedGoogle Scholar
  • 75 Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12 (Suppl 6) 54-61
    CrossrefPubMedGoogle Scholar
  • 76 Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16 (Suppl 2) 16-23
    CrossrefPubMedGoogle Scholar
  • 77 Gringeri A, Mantovani LG, Scalone L, Mannucci PM ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 78 Scalone L, Mantovani LG, Mannucci PM, Gringeri A ; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12 (2) 154-162
    PubMedGoogle Scholar
  • 79 Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl 1) 13-19
    PubMedGoogle Scholar
  • 80 Matzinger P. The danger model: a renewed sense of self. Science 2002; 296 (5566) 301-305
    CrossrefPubMedGoogle Scholar
  • 81 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 82 Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5 (7) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 83 Gouw SC, van den Berg HM, van der Bom JG. on behalf of the PedNet Study Group and the RODIN Study Group. Treatment-related risk factors of inhibitor development in patients with severe hemophilia A: the RODIN Study. J Thromb Haemost 2011; 9 (Suppl 2) 21
    CrossrefPubMedGoogle Scholar
  • 84 Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91 (8) 910-914
    CrossrefPubMedGoogle Scholar
  • 85 Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11 (2) 79-83
    CrossrefPubMedGoogle Scholar
  • 86 Santagostino E, Mancuso ME, Rocino A , et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130 (3) 422-427
    CrossrefPubMedGoogle Scholar
  • 87 Maclean PS, Richards M, Williams M , et al; Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17 (2) 282-287
    CrossrefPubMedGoogle Scholar
  • 88 Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16 (2) 256-262
    CrossrefPubMedGoogle Scholar
  • 89 Plug I, van der Bom JG, Peters M , et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104 (12) 3494-3500
    CrossrefPubMedGoogle Scholar
  • 90 Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD ; Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14 (5) 923-930
    CrossrefPubMedGoogle Scholar
  • 91 Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy—a survey of treatment centres in the United States. Haemophilia 2003; 9 (5) 549-554
    CrossrefPubMedGoogle Scholar
  • 92 Taki M, Shirahata A. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Haemophilia 2009; 15 (1) 78-82
    CrossrefPubMedGoogle Scholar
  • 93 Fischer K, van der Bom JG, Molho P , et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8 (6) 745-752
    CrossrefPubMedGoogle Scholar
  • 94 Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14 (4) 743-752
    CrossrefPubMedGoogle Scholar
  • 95 van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11 (5) 438-443
    CrossrefPubMedGoogle Scholar
  • 96 Fischer K, Van Der Bom JG, Prejs R , et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7 (6) 544-550
    CrossrefPubMedGoogle Scholar
  • 97 van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130 (1) 107-112
    CrossrefPubMedGoogle Scholar
  • 98 Santagostino E, Mancuso ME, Tripodi A , et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (4) 737-743
    CrossrefPubMedGoogle Scholar
  • 99 Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14 (Suppl 3) 196-201
    CrossrefPubMedGoogle Scholar
  • 100 Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10 (2) 134-146
    CrossrefPubMedGoogle Scholar
  • 101 Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138 (5) 580-586
    CrossrefPubMedGoogle Scholar
  • 102 Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141 (5) 689-695
    CrossrefPubMedGoogle Scholar
  • 103 Ljung R, Chambost H, Stain AM, DiMichele D. Haemophilia in the first years of life. Haemophilia 2008; 14 (Suppl 3) 188-195
    CrossrefPubMedGoogle Scholar
  • 104 Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 2009; 94 (5) 687-692
    CrossrefPubMedGoogle Scholar
  • 105 Bui S, Babre F, Hauchecorne S , et al. Intravenous peripherally-inserted central catheters for antibiotic therapy in children with cystic fibrosis. J Cyst Fibros 2009; 8 (5) 326-331
    CrossrefPubMedGoogle Scholar
  • 106 Hatakeyama N, Hori T, Yamamoto M , et al. An evaluation of peripherally inserted central venous catheters for children with cancer requiring long-term venous access. Int J Hematol 2011; 94 (4) 372-377
    CrossrefPubMedGoogle Scholar
  • 107 Fischer K, Astermark J, van der Bom JG , et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8 (6) 753-760
    CrossrefPubMedGoogle Scholar
  • 108 van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9 (Suppl 1) 27-31, discussion 31
    CrossrefPubMedGoogle Scholar
  • 109 Wu R, Luke KH, Poon M-C , et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011; 17 (1) 70-74
    CrossrefPubMedGoogle Scholar
  • 110 Celkan T, Özdemir N. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey. Haemophilia 2011; 17 (5) e840-e841
    PubMedGoogle Scholar
  • 111 National Hemophilia Foundation. Medical and Scientific Advisory Council. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Recommendation 179. (2007). Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007 . Accessed on September 16, 2011
    PubMedGoogle Scholar
  • 112 Tagariello G, Iorio A, Santagostino E , et al; Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114 (4) 779-784
    CrossrefPubMedGoogle Scholar
  • 113 den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15 (1) 83-90
    CrossrefPubMedGoogle Scholar
  • 114 Konkle BA, Ebbesen LS, Erhardtsen E , et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5 (9) 1904-1913
    CrossrefPubMedGoogle Scholar
  • 115 Leissinger C, Gringeri A, Antmen B , et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
    CrossrefPubMedGoogle Scholar
  • 116 Jiménez-Yuste V, Alvarez MT, Martín-Salces M , et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15 (1) 203-209
    CrossrefPubMedGoogle Scholar
  • 117 Santagostino E, Auerswald G, Jimenez-Yuste V , et al. European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) – a prospective study. Haemophilia 2010; 16 (2) 407
    PubMedGoogle Scholar
  • 118 Nicholson A, Berger K, Bohn R , et al. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia 2008; 14 (1) 127-132
    PubMedGoogle Scholar
  • 119 Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010; 2010: 203-209
    CrossrefPubMedGoogle Scholar